115 related articles for article (PubMed ID: 37704591)
1. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Glytsou C; Chen X; Zacharioudakis E; Al-Santli W; Zhou H; Nadorp B; Lee S; Lasry A; Sun Z; Papaioannou D; Cammer M; Wang K; Zal T; Zal MA; Carter BZ; Ishizawa J; Tibes R; Tsirigos A; Andreeff M; Gavathiotis E; Aifantis I
Cancer Discov; 2023 Jul; 13(7):1656-1677. PubMed ID: 37088914
[TBL] [Abstract][Full Text] [Related]
2. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
[TBL] [Abstract][Full Text] [Related]
3. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P; Lu A; Suh SM; Dong VM; Roberts AW; Leverson JD; Jalaluddin M; Liu Z; Bueno OF; Boise LH; Fruman DA
Cancer Res Commun; 2023 Dec; 3(12):2497-2509. PubMed ID: 37956312
[TBL] [Abstract][Full Text] [Related]
4. The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death.
Jia J; Li M; Li Y; Xiao J; Dai H
Cell Biol Toxicol; 2023 Dec; 39(6):2821-2839. PubMed ID: 37002446
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Panobinostat on Cell Death in Combination with S63845 in Multiple Myeloma Cells.
Tagoug A; Safra I
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):245-257. PubMed ID: 37006981
[TBL] [Abstract][Full Text] [Related]
6. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.
Spaan I; Timmerman LM; Kimman T; Slomp A; Cuenca M; van Nieuwenhuijzen N; Moesbergen LM; Minnema MC; Raymakers RA; Peperzak V
Blood Adv; 2021 Jun; 5(12):2593-2607. PubMed ID: 34152396
[TBL] [Abstract][Full Text] [Related]
7. Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer.
Howard D; James D; Murphy K; Garcia-Parra J; Pan-Castillo B; Rex S; Moul A; Jones E; Bilbao-Asensio M; Michue-Seijas S; Lutchman-Singh K; Margarit L; Francis LW; Rees P; Gonzalez D; Conlan RS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800911
[TBL] [Abstract][Full Text] [Related]
8. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; ; ;
Haematologica; 2024 Mar; ():. PubMed ID: 38511268
[TBL] [Abstract][Full Text] [Related]
9. PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro.
Perry JR; Genenger B; Thind AS; Ashford B; Ranson M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254859
[TBL] [Abstract][Full Text] [Related]
10. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract][Full Text] [Related]
12. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
13. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
[TBL] [Abstract][Full Text] [Related]
14. Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X
Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
[TBL] [Abstract][Full Text] [Related]
15. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
